ğŸ§® Step 1. Coefficient summary (from your GEE)
Variable	Coefficient	p-value	Interpretation
Intercept	1.30	0.00	Baseline log-odds of conversion for a control member with average prescriber share and not new.
is_target_member	+0.22	0.00	Direct effect of being targeted (vs control), when prescriberâ€™s target share = 0.
presc_target_share	+0.156	0.034	Spillover effect: control members convert more when their prescriber has more targeted patients.
is_target_member Ã— presc_target_share	â€“0.375	0.00	Interaction: effect of being targeted shrinks (or even reverses) as prescriberâ€™s exposure increases.
is_new_member	+0.298	0.00	New members are more likely to convert overall.
ğŸ” Step 2. Expressed in human terms

Letâ€™s define:

ğ‘‡
ğ‘–
=
1
T
i
	â€‹

=1 if member is targeted.

ğ‘†
ğ‘—
S
j
	â€‹

 = prescriberâ€™s target share (between 0â€“1).

ğ‘Œ
=
Y= log-odds(EDS conversion).

Then your model implies:

logit
(
ğ‘ƒ
(
convert
)
)
=
1.30
+
0.22
ğ‘‡
+
0.156
ğ‘†
âˆ’
0.375
(
ğ‘‡
Ã—
ğ‘†
)
+
0.298
(
new member
)
logit(P(convert))=1.30+0.22T+0.156Sâˆ’0.375(TÃ—S)+0.298(new member)
âœ… For a control member (T = 0)
logit
(
ğ‘ƒ
)
=
1.30
+
0.156
ğ‘†
+
0.298
(
new
)
logit(P)=1.30+0.156S+0.298(new)

â†’ Control members benefit modestly when prescriber has more targeted patients â€” this is the spillover effect (prescribers change behavior even for control patients).

âœ… For a targeted member (T = 1)
logit
(
ğ‘ƒ
)
=
1.30
+
(
0.22
)
+
(
0.156
âˆ’
0.375
)
ğ‘†
+
0.298
(
new
)
logit(P)=1.30+(0.22)+(0.156âˆ’0.375)S+0.298(new)
logit
(
ğ‘ƒ
)
=
1.52
âˆ’
0.219
ğ‘†
+
0.298
(
new
)
logit(P)=1.52âˆ’0.219S+0.298(new)

So as 
ğ‘†
S (prescriber exposure) increases, the incremental benefit of targeting that member declines.

ğŸ§  Step 3. Why does the negative interaction make sense (statistically and behaviorally)?

This is one of the most common findings in partial interference experiments â€” and itâ€™s actually interpretable if you think of diminishing marginal returns.

Possible real-world explanations:

Prescriber-level saturation / ceiling effect
When many of a prescriberâ€™s patients are targeted, that prescriber has already changed behavior â€” so targeting another member under that prescriber yields less additional lift.
â†’ The marginal impact of â€œmember being targetedâ€ goes down as prescriberâ€™s exposure increases.

Indirect spillover already covers most of the benefit
High prescriber exposure â†’ control members get improved outcomes (the +0.156).
That means the â€œgapâ€ between targeted vs control members narrows, producing a negative interaction.

Campaign overlap
Prescribers with high target shares might receive many EHR alerts or messages â€” after a certain saturation, alerts may be ignored, reducing incremental impact.

Statistical perspective
Interaction term captures how the slope of is_target_member changes with prescriber_share.
If prescriber_share and is_target_member are correlated (common, because many members share same prescriber), the negative sign may partly reflect this collinearity â€” essentially the model â€œshares creditâ€ between the spillover and direct effects.

ğŸ“ˆ Step 4. Quantify with example probabilities

Letâ€™s estimate approximate predicted probabilities (assuming is_new_member = 0, for clarity):

presc_target_share	Control (T=0)	Targeted (T=1)	Lift (Î”)
0.0	logitâ»Â¹(1.30) = 0.79	logitâ»Â¹(1.52) = 0.82	+3%
0.5	logitâ»Â¹(1.30+0.156Ã—0.5)=0.81	logitâ»Â¹(1.52-0.219Ã—0.5)=0.81	0%
1.0	logitâ»Â¹(1.30+0.156)=0.81	logitâ»Â¹(1.52-0.219)=0.80	-1%

â¡ï¸ So when prescriber exposure is low (few of their patients targeted), targeting helps (+3%).
When prescriber exposure is high, everyone benefits a bit (spillover), but direct targeting adds no extra effect â€” consistent with saturation.
